INK-128 is an ATP-competitive inhibitor of mTOR, inhibiting both mTORC1 and mTORC2, protein complexes that modulate cell growth, cell survival, and cell migration. This compound displays anticancer chemotherapeutic and anti-metastatic activities in both in vitro and in vivo models. In vitro, INK-128 inhibits cell migration and adhesion, processes critical for the invasive nature of multiple myeloma; INK-128 also inhibits proliferation and decreases colony formation in an in vitro model of B-cell acute lymphoblastic leukemia. In vivo, INK-128 decreased metastases in an animal model of prostate cancer. This compound is currently in clinical trials as a potential treatment for multiple myeloma.